Résumé
Objective To investigate the clinical curative effect of Weipixiao for the treatment of chronic atrophic gastritis (CAG). Methods A total of 58 CAG patients with spleen-stomach deficiency syndrome was evenly randomized into Weipixiao group and Weifuchun group. Weipixiao group was treated with Weipixiao decoction orally,and Weifuchun group was treated with Weifuchun tablets orally. The treatment time covered 12 weeks. The scores of symptoms and pathology of CAG patients were graded before and after treatment. The clinical efficacy was evaluated with the symptom scores and pathological scores. Results (1)The scores of primary symptoms and secondary symptoms in the two groups were obviously decreased after treatment (P < 0.05 compared with those before treatment),and the decrease in Weipixiao group was superior to that in Weifuchun group(P< 0.05).(2) The total effective rate for clinical efficacy in Weipixiao group and Weifuchun group was 96.55%, 93.10%respectively, the difference being significant (P < 0.05). (3)After treatment, the scores of gastric mucosal atrophy and intestinal metaplasia in the two groups were obviously decreased after treatment (P < 0.05 compared with those before treatment),and the scores of gastric mucosal atypical hyperplasia were decreased obviously in Weipixiao group(P<0.05) but not obviously in Weifuchun group(P>0.05). The inter-group comparison results showed that Weipixiao group had better effect on decreasing gastric mucosal atrophy scores than Weifuchun group(P<0.05). Conclusion Weipixiao has good curative effect for the treatment of CAG patients with spleen-stomach deficiency syndrome through relieving the symptoms and improving the pathological changes of gastric mucosal atrophy and intestinal metaplasia.